ArticleDigestive diseases and sciences2017
Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.
Article in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Pandemic-Related Disruptions and Hepatocellular Carcinoma Surveillance in Safety-Net Settings.JAMA network open · 2026Article
- Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis at US Safety-Net Health Systems.Clinical and translational gastroenterology · 2025Article
- Changes in the ultrasound presentation of hepatocellular carcinoma: a center's three decades of experience.Journal of ultrasound · 2024Article
- Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review.Journal of gastrointestinal cancer · 2023Article
- Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients.World journal of gastrointestinal oncology · 2021Article
- Identifying Quality Gaps in Preventive Care for Outpatients With Cirrhosis Within a Large, Academic Health Care System.Hepatology communications · 2020Article
- Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT.BMC gastroenterology · 2020Article
- Effect of Nonalcoholic Fatty Liver Disease and Metabolic Risk Factors on Waitlist Outcomes in Patients With Hepatocellular Carcinoma.Transplantation direct · 2020Article
- Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.Diagnostics (Basel, Switzerland) · 2020Review
- Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma.JGH open : an open access journal of gastroenterology and hepatology · 2020Review
- AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.Gastroenterology · 2020Review
- Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States.Hepatology communications · 2019Article
- One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation.World journal of hepatology · 2018Article
- A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care.Hepatology communications · 2018Article
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history.Hepatobiliary surgery and nutrition · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisparities in receipt of hepatocellular carcinoma (HCC) surveillance contribute to disparities in overall survival outcomes.
aimWe aim to evaluate disparities in receipt of routine HCC surveillance among patients with cirrhosis in a large urban safety-net hospital.
methodsConsecutive adults (age ≥ 18) with cirrhosis from July 1, 2014, to December 31, 2015, were retrospectively evaluated to determine rates of receiving appropriate HCC surveillance within 6 months and 1 year after diagnosis of cirrhosis. Rates of HCC surveillance were stratified by sex, race/ethnicity, and liver disease etiology. Multivariate Cox proportional hazards models were utilized to evaluate for predictors of receiving appropriate HCC surveillance.
resultsAmong 157 cirrhosis patients enrolled [hepatitis C virus (HCV): 29.9%, hepatitis B virus: 13.4%, alcoholic cirrhosis: 44.6%, nonalcoholic steatohepatitis (NASH): 8.9%], mean age of cirrhosis diagnosis was 53.8 ± 9.0 years. Among these patients, 49% received (n = 77) HCC surveillance within 6 months and 78% (n = 123) were surveyed within 1 year of cirrhosis diagnosis. On multivariate analyses, patients with NASH cirrhosis were significantly less likely to receive HCC surveillance compared with chronic HCV cirrhosis patients (HR 0.44, 95% CI 0.19-0.99, p < 0.05). No significant sex-specific or race/ethnicity-specific disparities in receipt of HCC surveillance were observed.
conclusionAmong a diverse safety-net hospital population, sub-optimal HCC surveillance rates were observed: Only 49% of cirrhosis patients received HCC surveillance within 6 months, and 78% of cirrhosis patients received HCC surveillance within 1 year. Differences in rates of HCC screening by liver disease etiology were observed.
Indexed as
Identifiers
28474143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.